Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSLN STAR-T Cells in Advanced Malignant Solid Tumors
NCT05344976Phase 1Not yet recruiting
- Sponsor
- Peking University
- Start
- Apr 2022
- Primary completion
- Oct 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label trial of MSLN STAR-T cells in malignant solid tumor, mesothelioma, pancreatic cancer (PC) and 6 more, sponsored by Peking University. Primary endpoint: Adverse Events at 3 months. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
MSLN STAR-T cells
03
Conditions
malignant solid tumormesotheliomapancreatic cancer (PC)ovarian cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05344976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05344976.